Interleukin-6: A Potential Biomarker for Dysmenorrhea and Disease Severity in Adenomyosis

Ying Tang, Huayu Tian, Hua-dong Tian, Bin Su, Hongbo He, Xin Cai, Huiquan Hu, Jun Li
In: Research Square · 2025 · doi:10.21203/rs.3.rs-7472436/v1 · W4415408969
preprint OA: green CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This study found that elevated serum interleukin-6 levels are associated with dysmenorrhea and increased uterus volume in adenomyosis patients, suggesting IL-6 as a potential biomarker for disease severity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This retrospective study analyzed 173 women with MRI- or ultrasound-diagnosed adenomyosis to test whether serum interleukin-6 (IL-6) is associated with dysmenorrhea and to identify factors related to IL-6 levels, using ELISA/flow microsphere assays and ROC curve plus logistic and multivariate regression analyses. IL-6 levels were significantly higher in patients with dysmenorrhea than without dysmenorrhea across the total cohort and within both diffuse and focal lesion subtypes, and an IL-6 cutoff of 3.02 pg/mL best discriminated dysmenorrhea; IL-6 also positively correlated with uterine volume, particularly in the total and diffuse groups. The authors’ key caveats include preoperative retrospective design, selection/exclusion criteria (e.g., excluding intrapelvic endometriosis), and the focus on single time-point serum IL-6 measured within 24 hours before FUAS. This paper is centrally about endometriosis: it explicitly excludes intrapelvic endometriosis and focuses on inflammatory biomarker IL-6 in adenomyosis-related dysmenorrhea and disease severity.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Source provenance

europepmc
last seen: 2026-06-04T01:45:00.660873+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK